BRAIN Biotech

BRAIN Biotech FCF per Share

The Free Cash Flow per Share of BRAIN Biotech (BNN.DE) as of Nov 5, 2026 is -0.49 EUR. In the previous year, Free Cash Flow per Share was -0.24 EUR — a change of 102.64% (lower).

FCF per Share

-0.49EUR

YoY

102.64%

Last updated:

Free Cash Flow per Share of BRAIN Biotech is 2025 -0.49 EUR. Free Cash Flow per Share of BRAIN Biotech was 2024 -0.24 EUR. It decreases by 102.64% lower compared to the previous year.

The BRAIN Biotech FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-0.38 EUR
Jan 1, 2019
-0.55 EUR
Jan 1, 2020
-0.38 EUR
Jan 1, 2021
-0.24 EUR
Jan 1, 2022
-0.35 EUR
Jan 1, 2023
-0.31 EUR
Jan 1, 2024
-0.24 EUR
Jan 1, 2025
-0.49 EUR
The BRAIN Biotech FCF per Share history
YEARFCF per ShareYoY
-0.49EUR+102.64%
-0.24EUR-22.52%
-0.31EUR-9.40%
-0.35EUR+46.42%
-0.24EUR-38.39%
-0.38EUR-30.79%
-0.55EUR+44.52%
-0.38EUR+1.40%
-0.38EUR-37.33%
-0.60EUR+65.10%
-0.37EUR+5.86%
-0.35EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BRAIN Biotech Stock analysis

What does BRAIN Biotech do? The company BRAIN Biotechnology Research and Information Network AG is a German company specializing in biotechnology. The company was founded in 1993 and is headquartered in Zwingenberg, Germany. BRAIN has been listed on the Frankfurt Stock Exchange since 2006 and has over 500 employees worldwide. The history of BRAIN dates back to the 1980s when the Senckenberg Institute for Biodiversity and Climate Research in Frankfurt developed a new method for isolating microorganisms. These are called extremophilic bacteria and fungi, which live in extreme environments such as hot springs or salty soils and produce special enzymes. These enzymes can be used in various applications, such as the food industry or the development of new drugs. BRAIN has further developed this method and built an extensive portfolio of enzymes, microorganisms, and natural substances. The company is divided into three areas: 1. BioIndustrial: Enzymes and microorganisms for industrial applications are developed here, such as for the production of detergents, paper, or bioethanol. 2. BioScience: This area focuses on the research of natural substances and active ingredients from microorganisms for the pharmaceutical and cosmetics industries. 3. Consumer Products: BRAIN develops products for end consumers here, such as probiotics or enzyme preparations for digestion promotion. BRAIN works closely with leading companies to develop innovative solutions for their needs. The company is not only focused on the development of new products but also on the optimization of existing processes. BRAIN relies on sustainable and environmentally friendly production. An example of a product developed by BRAIN is an enzyme used in the production of fruit juice. This enzyme breaks down pectin, which is found in many types of fruit and causes the juice to become cloudy. By using this enzyme, the juice can be made clearer and more durable without the need for artificial additives. BRAIN also uses a special enzyme in the production of soy milk to improve taste and consistency. Overall, BRAIN has filed over 600 patents and works with more than 170 customers in various industries. The company is committed to preserving biodiversity and promoting sustainability in production. In summary, BRAIN Biotechnology Research and Information Network AG is a company specializing in the research and development of enzymes, microorganisms, and natural substances. The company has a long history and can look back on successful collaborations with leading companies in various industries. BRAIN focuses on sustainability and environmental compatibility in production and has a broad portfolio of products that can be used in various applications. BRAIN Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BRAIN Biotech stock

Free Cash Flow per Share of BRAIN Biotech is -0.49 EUR in 2025.

Free Cash Flow per Share of BRAIN Biotech changed from -0.24 EUR to -0.49 EUR, representing a 102.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share BRAIN Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BRAIN Biotech

All Key Metrics — BRAIN Biotech